Published in Semin Nucl Med on July 01, 2005
Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging (2007) 1.12
Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2006) 1.02
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer (2013) 1.00
Periaortic lymphoma as a mimic of posttraumatic intramural hematoma. Emerg Radiol (2006) 0.81
High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2013) 0.81
PET in lymphoma. Cancer Imaging (2006) 0.77
Multicenter Comparison of Contrast-Enhanced FDG PET/CT and 64-Slice Multi-Detector-Row CT for Initial Staging and Response Evaluation at the End of Treatment in Patients With Lymphoma. Clin Nucl Med (2017) 0.75
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med (2013) 8.89
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.08
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol (2005) 3.47
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood (2013) 3.23
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol (2004) 2.90
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood (2012) 2.21
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica (2007) 2.05
ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood (2003) 2.05
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly? Leuk Lymphoma (2014) 1.99
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica (2005) 1.92
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol (2007) 1.76
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis (2010) 1.70
18F-FDG PET in candidates for radiation therapy: is it important and how do we validate its impact? J Nucl Med (2003) 1.69
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood (2011) 1.69
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood (2008) 1.64
Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys (2004) 1.64
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med (2002) 1.62
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood (2004) 1.57
Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma (2003) 1.52
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer (2011) 1.51
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol (2010) 1.50
Surveillance for catheter-associated bloodstream infection in hematology units: quantifying the characteristics of a practical case definition. Infect Control Hosp Epidemiol (2008) 1.47
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. Leuk Lymphoma (2014) 1.47
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood (2006) 1.47
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia. Leuk Lymphoma (2010) 1.41
Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era. J Clin Oncol (2013) 1.39
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol (2009) 1.24
Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Haematol (2007) 1.19
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res (2006) 1.19
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica (2013) 1.18
Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica (2006) 1.17
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood (2013) 1.15
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol (2006) 1.14
Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma. Int J Radiat Oncol Biol Phys (2008) 1.14
Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol (2010) 1.12
Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging (2007) 1.12
Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood (2007) 1.12
Pulmonary alveolar proteinosis. Clin Chest Med (2004) 1.11
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol (2006) 1.09
The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. Br J Haematol (2008) 1.09
Let's get SEERious: more accurate staging with consequent high management impact is not just stage migration. J Clin Oncol (2013) 1.08
Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol (2013) 1.08
Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices. Support Care Cancer (2008) 1.07
The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol (2006) 1.05
Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys (2008) 1.04
Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J Immunol (2006) 1.04
Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data. J Nucl Med (2012) 1.04
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer (2006) 1.03
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica (2005) 1.02
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol (2010) 1.02
Management of the primary cutaneous lymphomas. Australas J Dermatol (2003) 1.00
Mice lacking three myeloid colony-stimulating factors (G-CSF, GM-CSF, and M-CSF) still produce macrophages and granulocytes and mount an inflammatory response in a sterile model of peritonitis. J Immunol (2007) 1.00
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res (2008) 0.99
Primary testicular lymphoma. Blood (2013) 0.97
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica (2011) 0.96
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood (2003) 0.93
Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. J Antimicrob Chemother (2013) 0.91
Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency. Acta Haematol (2013) 0.91
Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood (2002) 0.91
Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol (2009) 0.91
Complete remission of localised gastric plasmacytomas following definitive radiotherapy. J Med Imaging Radiat Oncol (2012) 0.90
Progress in primary CNS lymphoma. Lancet (2009) 0.90
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol (2006) 0.90
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma (2012) 0.90
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma (2012) 0.89
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res (2005) 0.89
Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. Clin Lymphoma Myeloma (2006) 0.89
Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. Ann Hematol (2004) 0.88
Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin Cancer Res (2004) 0.88
Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma (2002) 0.87
Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med (2004) 0.87
Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome. Leuk Lymphoma (2012) 0.86
Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia. J Hematol Oncol (2008) 0.85
Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge. Leuk Lymphoma (2010) 0.85
Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention. Med J Aust (2005) 0.84
Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. BMC Pulm Med (2014) 0.84
Progressive multifocal leukoencephalopathy complicating Waldenström's macroglobulinaemia. Leuk Lymphoma (2003) 0.83
Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells. Br J Haematol (2004) 0.82
Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. Leuk Lymphoma (2009) 0.82
Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when? Curr Oncol Rep (2015) 0.81
Legionella pneumophila mip gene sequencing to investigate a cluster of pneumonia cases. Pathology (2003) 0.81
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment. Aust Health Rev (2011) 0.81
Fertility preservation in female oncology patients. Aust N Z J Obstet Gynaecol (2006) 0.81
Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Ann Hematol (2008) 0.81
Predicting durable remissions following thalidomide therapy for relapsed myeloma. Leuk Lymphoma (2009) 0.81
High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2013) 0.81
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leuk Lymphoma (2006) 0.81
No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia. Leuk Lymphoma (2012) 0.80
Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia. Clin Lymphoma Myeloma (2005) 0.80